Physician profile
Christopher Wofford
NPI 1427195171
$1,361.90
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.26 · 2020: $101 · 2021: $163 · 2022: $539 · 2023: $292 · 2024: $125 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.68 | 2021-2025 | Ubrelvy |
| Abbott Laboratories | $183.98 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $158.00 | 2021-2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $116.79 | 2022 | |
| Medtronic, INC. | $116.11 | 2022-2024 | Linq II |
| Lilly USA, LLC | $76.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $60.15 | 2020-2023 | Farxiga |
| Corium, LLC | $50.05 | 2023 | Azstarys |
| Amarin Pharma, INC. | $45.49 | 2020-2021 | |
| Glaxosmithkline, LLC. | $44.35 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Sk Life Science, INC. | $37.66 | 2022 | |
| Amgen INC. | $35.80 | 2022-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $29.46 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $26.90 | 2022 | |
| Antares Pharma, INC. | $20.09 | 2023 | Tlando, Xyosted, Nocdurna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.45 | 2023 | Cologuard Collection Kit |
| Nevro Corp. | $17.56 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $17.19 | 2023 | Quviviq |
| Pfizer INC. | $14.03 | 2023 | |
| Ibsa Pharma INC. | $13.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wofford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.